The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

29 Aug 2008 16:00

RNS Number : 3409C
Cathay International Holdings Ld
29 August 2008
 



29 August 2008

CATHAY INTERNATIONAL HOLDINGS LIMITED

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2008

 
 
Pharmaceutical
 
 
 
 
 
Production
 
 
 
Hotel
Research &
marketing &
Corporate
 
 
Operations
development
distribution
Office
Total
(Stated in USD’000)
 
 
 
 
 
 
 
 
 
 
 
Forthesixmonthsended30June2008
 
 
 
 
 
Revenue
4,520
25,001
29,521
Segmentgrossprofit
575
12,385
12,960
Segmentoperatingprofit/(loss)
627
(521)
2,245
(1,087)
1,264
Segmentfinancecostsnet
 (1,060)
2
(1,043)
(1,393)
(3,494)
Segmentprofit/(loss)beforeincometax
 (433)
(519)
1,202
(2,480)
(2,230)
 
 
 
 
 
 
Forthesixmonthsended30June2007
 
 
 
 
 
Revenue
3,387
10,031
13,418
Segmentgrossprofit/(loss)
(366)
6,903
6,537
Segmentoperatingprofit/(loss)
(230)
(541)
 844
(1,356)
(1,283)
Segmentfinancecostsnet
(837)
(247)
(972)
(2,056)
Segmentprofit/(loss)beforeincometax
(1,067)
(541)
 597
(2,328)
(3,339)
 
 
 
 
 
 
Fortheyearended31December2007
 
 
 
 
 
Revenue
7,495
26,684
34,179
Segmentgrossprofit/(loss)
(769)
16,833
16,064
Segmentoperatingprofit/(loss)
(674)
(1,213)
784
(1,844)
(2,947)
Shareoflossofanassociate
(21)
(21)
Segmentfinancecostsnet
(1,630)
2
(830)
(2,469)
(4,927)
Segmentlossbeforeincometax
(2,304)
(1,211)
(67)
(4,313)
(7,895)
 
 
 
 
 
 

 

Gross turnover for the six months ended 30 June 2008 was USD29,521,000 compared with USD13,418,000 for the six months ended 30 June 2007. The increase in turnover was the result of :

i) 66% growth in sales of the existing pharmaceutical production, marketing and distribution businesses of Liwah and Lansen;

ii) growth in sales of Crowne Plaza Hotel & Suites Landmark Shenzhen.

The Group's gross profit for the six month period was USD12,960,000 (2007: USD6,537,000). The increase was due to growth in sales of pharmaceutical products and to an increased contribution from the hotel sector.

The Group recorded an operating profit of USD1,264,000 (2007: loss of USD1,283,000). The pharmaceutical production, marketing and distribution businesses increased operating profit to USD2,245,000 (2007: USD844,000). Corporate office expenses and salaries have been stable when compared to the same period last year.

The Group's loss before income tax for the six month period was USD2,230,000 (2007: loss of USD3,339,000). The reduction of the gross loss was mainly due to increased contributions from the hotel and pharmaceutical production, marketing and distribution sectors.

The finance costs for the six month period were USD3,494,000 (2007: USD2,056,000). The increase was due to the higher utilisation of bank facilities.

BIOTECHNOLOGY AND PHARMACEUTICAL BUSINESS

Ningbo Liwah Pharmaceutical Company Limited ("Liwah") and Lansen Medicine (Shenzhen) Company Limited ("Lansen") continue to be the major contributors to the Group's pharmaceutical business. Their business grew by 66% when compared to the same period in 2007.

The gross profit margin of the Liwah and Lansen pharmaceutical business was 70% (2007: 69%).

CROWNE PLAZA HOTEL & SUITES LANDMARK SHENZHEN

The Shenzhen hotel industry remains highly competitive. In addition, the hotel industry in China was adversely affected by the Sichuan earthquake in May which reduced travel and entertainment throughout China. The travel industry expected the number of foreign visitors to increase in the run up to and during the Olympic Games. However, the Chinese government, in the interests of security for the Games, imposed stringent restrictions on the issuance of foreign visas in the second quarter of 2008. This resulted in the cancellation of numerous business conferences and seminars across China and sharply reduced the expected number of business travellers. This in turn led to reduced occupancy levels at our hotel.

Despite the difficult operating environment, we are pleased to report that the InterContinental Hotels Group ("IHG"), which has been managing the hotel since 18 December 2007, has achieved an average occupancy rate of 43% (2007: 34%) and an average room rate of USD130 (2007: USD118) for the first six months of 2008. The hotel's profit from operations for the first six months of 2008 was USD627,000 (2007: loss of USD230,000).

In accordance with our usual practice, the Group will conduct an annual valuation of the hotel at the year end.

BANK FACILITIES

In June 2008, the Group obtained a 3-5 year banking facility in the amount of USD22 million. The facility will be used to re-finance existing loans and for corporate funding requirements.

CONCLUSION

The Board believes that it is well positioned for continued expansion in the pharmaceutical industry in China. With regard to the hotel business, the Board is of the view that IHG is already having a positive impact on performance in a very difficult market. As conditions return to normal in China, we expect enhanced hotel results.

On behalf of the Board, I would like to thank our management and staff for their continued dedication and commitment.

James Buchanan

Chairman

Enquiries: 

 

Stephen Hunt (Deputy Chairman) (via Brunswick) 020 7404 5959

Patrick Sung (Director - Finance)

GROUP CONDENSED INCOME STATEMENT

 
 
Six months
Six months
Year ended
 
 
ended 30 June
ended 30 June
31 December
 
 
2008
2007
2007
 
 
(Unaudited)
(Unaudited)
(Audited)
 
Note
USD'000
USD'000
USD'000
 
 
 
 
 
REVENUE
2
29,521
13,418
34,179
COST OF SALES
 
(16,561)
(6,881)
(18,115)
GROSS PROFIT
 
12,960
6,537
16,064
SELLING AND DISTRIBUTION EXPENSES
 
(6,835)
(4,368)
(10,323)
ADMINISTRATIVE EXPENSES
 
(4,633)
(3,287)
(6,025)
PROVISION FOR DOUBTFUL DEBTS
 
(228)
(165)
(2,663)
PROFIT/ (LOSS) FROM OPERATIONS
 
1,264
(1,283)
(2,947)
SHARE OF LOSS OF AN ASSOCIATE
 
-
-
(21)
FINANCE COSTS - NET
 
(3,494)
(2,056)
(4,927)
LOSS BEFORE INCOME TAX
2
(2,230)
(3,339)
(7,895)
INCOME TAX EXPENSE
3
(385)
(178)
(370)
LOSS FOR THE PERIOD
 
(2,615)
(3,517)
(8,265)
 
 
 
 
 
ATTRIBUTABLE TO:
 
 
 
 
EQUITY SHAREHOLDERS OF THE PARENT
 
(2,411)
(3,504)
(8,026)
MINORITY INTERESTS
 
(204)
(13)
(239)
 
 
(2,615)
(3,517)
(8,265)
 
 
 
 
 
LOSS PER SHARE ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE PARENT
4
 
 
 
BASIC
 
(0.87) cents
(1.27) cents
(2.91) cents
DILUTED
 
N/A
N/A
N/A

GROUP CONDENSED BALANCE SHEET

 
 
 
As at
 
As at
 
As at
 
 
 
30 June
 
30 June
 
31 December
 
 
 
2008
 
2007
 
2007
 
 
 
(Unaudited)
 
(Unaudited)
 
(Audited)
 
 
 
USD'000
 
USD'000
 
USD'000
ASSETS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NON-CURRENT ASSETS
 
 
 
 
 
 
 
Property, plant and equipment
 
 
153,299
 
147,336
 
147,843
Land use rights
 
 
3,099
 
1,801
 
2,953
Investment property
 
 
1,553
 
1,405
 
1,464
Intangible assets
 
 
1,386
 
499
 
1,299
Goodwill
 
 
9,156
 
7,781
 
8,702
Interest in an associate
 
 
-
 
-
 
804
Loans to minority shareholders
 
 
645
 
674
 
645
 
 
 
169,138
 
159,496
 
163,710
 
 
 
 
 
 
 
 
CURRENT ASSETS
 
 
 
 
 
 
 
Inventories
 
 
8,336
 
2,149
 
8,559
Trade and other receivables
 
 
18,996
 
11,617
 
24,421
Land use rights
 
 
67
 
39
 
63
Pledged bank deposits
 
 
6,556
 
-
 
5,466
Cash and cash equivalents
 
 
11,483
 
1,412
 
11,247
 
 
 
45,438
 
15,217
 
49,756
 
 
 
 
 
 
 
 
TOTAL ASSETS
 
 
214,576
 
174,713
 
213,466
 
 
 
 
 
 
 
 
EQUITY AND LIABILITIES
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE PARENT
 
 
64,298
 
78,358
 
66,062
 
 
 
 
 
 
 
 
MINORITY INTERESTS
 
 
9,496
 
7,319
 
9,784
TOTAL EQUITY
 
 
73,794
 
85,677
 
75,846
 
 
 
 
 
 
 
 
NON-CURRENT LIABILITIES
 
 
 
 
 
 
 
Borrowings
 
 
50,536
 
2,121
 
41,410
Deferred tax liabilities
 
 
16,992
 
16,820
 
16,992
 
 
 
67,528
 
18,941
 
58,402
 
 
 
 
 
 
 
 
CURRENT LIABILITIES
 
 
 
 
 
 
 
Borrowings
 
 
29,998
 
29,506
 
36,823
Current tax liabilities
 
 
608
 
457
 
671
Trade and other payables
 
 
42,648
 
40,132
 
41,724
 
 
 
73,254
 
70,095
 
79,218
 
 
 
 
 
 
 
 
TOTAL LIABILITIES
 
 
140,782
 
89,036
 
137,620
TOTAL EQUITY AND LIABILITIES
 
 
214,576
 
174,713
 
213,466

GROUP CONDENSED STATEMENT OF CHANGES IN EQUITY

 

 
 
Minority
Total
 
Attributable to equity holders of the parent
Interests
Equity
 
 
 
Capital and
 
Exchange
 
Profit
 
 
 
 
Share
Share
Special
Revaluation
Equalisation
Statutory
and Loss
 
 
 
 
Capital
Premium
Reserve
Reserve
Reserve
Reserve
Account
Total
 
 
 
USD'000
USD'000
USD'000
USD'000
USD'000
USD'000
USD'000
USD'000
USD'000
USD'000
 
 
 
 
 
 
 
 
 
 
 
Balance at 1 January 2007
13,793
10,216
42,923
64,176
(14,529)
1,143
(35,830)
81,892
7,789
89,681
Exchange differences arising on
 translation of foreign currency
 operations
-
-
-
2,308
(2,371)
33
-
(30)
6
(24)
Net income recognised directly in
 equity
-
-
-
2,308
(2,371)
33
-
(30)
6
(24)
Loss for the period
-
-
-
-
-
-
(3,504)
(3,504)
(13)
(3,517)
Total recognised income and expenses
 
 
 
 
 
 
 
 
 
 
 for the period
-
-
-
2,308
 (2,371)
33
(3,504)
(3,534)
(7)
(3,541)
Deemed disposal of interest in
 subsidiaries
-
-
-
-
-
-
-
-
325
325
Buy back shares from minority
 interests
-
-
-
-
-
-
-
-
(788)
(788)
Transfer to statutory reserve
-
-
-
-
-
223
(223)
-
-
-
 
 
 
 
 
 
 
 
 
 
 
Balance at 30 June 2007
13,793
10,216
42,923
66,484
(16,900)
1,399
(39,557)
78,358
7,319
85,677
 
 
 
 
 
 
 
 
 
 
 
Balance at 1 January 2008
13,793
10,216
42,923
63,429
(21,692)
1,849
(44,456)
66,062
9,784
75,846
Exchange differences arising on
 
 
 
 
 
 
 
 
 
 
translation of foreign currency
 operations
-
-
1
4,689
(4,154)
111
-
647
(64)
583
Net income recognised directly in
 equity
-
-
1
4,689
(4,154)
111
-
647
(64)
583
Loss for the period
-
-
-
-
-
-
(2,411)
(2,411)
(204)
(2,615)
Total recognised income and expenses
 
 
 
 
 
 
 
 
 
 
 for the period
-
-
1
4,689
(4,154)
111
(2,411)
(1,764)
(268)
(2,032)
Acquisition of a subsidiary
-
-
-
-
-
-
-
-
104
104
Adjustments on goodwill
-
-
-
-
-
-
-
-
(124)
(124)
 
 
 
 
 
 
 
 
 
 
 
Balance at 30 June 2008
13,793
10,216
42,924
68,118
(25,846)
1,960
(46,867)
64,298
9,496
73,794

 

GROUP CONDENSED CASH FLOW STATEMENT

 
 
Six months
 
Six months
 
Year ended
 
 
ended 30 June
 
ended 30 June
 
31 December
 
 
2008
 
2007
 
2007
 
 
(Unaudited)
 
(Unaudited)
 
(Audited)
 
 
USD'000
 
USD'000
 
USD'000
 
 
 
 
 
 
 
Net cash generated from/(used in) operating activities
 
4,185
 
3,981
 
(13,926)
Net cash used in investing activities
 
(4,446)
 
(3,000)
 
(9,393)
Net cash (used in)/generated from financing activities
 
(756)
 
(2,054)
 
32,977
 
 
 
 
 
 
 
Net (decrease)/increase in cash and cash equivalents
 
(1,017)
 
(1,073)
 
9,658
Effects of exchange rate changes
 
1,248
 
527
 
(256)
Cash and cash equivalents at beginning of the period
 
11,125
 
1,723
 
1,723
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents at end of the period
 
11,356
 
1,177
 
11,125
 
 
 
 
 
 
 
Analysis of cash and cash equivalents
 
 
 
 
 
 
Cash and bank balances
 
11,483
 
1,412
 
11,247
Bank overdrafts
 
(127)
 
(235)
 
(122)
 
 
11,356
 
1,177
 
11,125

NOTES TO THE ACCOUNTS

 
1 BASIS OF PREPARATION
 
The interim condensed financial statements have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting and under the historical cost convention, modified where appropriate to incorporate a professional valuation of certain fixed assets.
 
The accounting policies adopted are consistent with those followed in the preparation of the Group’s annual financial statements for the year ended 31 December 2007. Certain comparative figures for the period ended 30 June 2007 in condensed financial statements have been reclassified to conform to the current period’s presentation. 
 
2 SEGMENTAL INFORMATION
 

 
Six months
Six months
Year ended
 
ended 30 June
ended 30 June
31 December
 
2008
2007
2007
 
(Unaudited)
(Unaudited)
(Audited)
 
USD'000
USD'000
USD'000
 
 
 
 
Revenue
 
 
 
Pharmaceutical:
 
 
 
Research & Development
-
-
-
Production, Marketing & Distribution
25,001
10,031
26,684
Hotel Operations
4,520
3,387
7,495
 
29,521
13,418
34,179
 
 
 
 
(Loss)/Profit before income tax
 
 
 
Pharmaceutical:
 
 
 
Research & Development
(519)
(541)
(1,211)
Production, Marketing & Distribution
1,202
597
(67)
Hotel Operations
(433)
(1,067)
(2,304)
Corporate Office
(2,480)
(2,328)
(4,313)
 
(2,230)
(3,339)
(7,895)
 
3 INCOME TAX EXPENSE
 
The provision for current tax has been made in respect of the assessable profits arising in the PRC during the period.
 
4 LOSS PER SHARE ATTRIBUTABLE TO EQUITY SHAREHOLDERS OF THE PARENT
 
Loss per share is based upon the loss after tax attributable to shareholders of USD2,411,000 for the six months ended 30 June 2008 (six months ended 30 June 2007: loss of USD3,504,000) and the weighted average number of A shares and common shares in issue during the period of 11,800,049 and 264,060,055 respectively (30 June 2007: A shares, common shares: 11,825,550 and 264,034,554).
 
No diluted earnings per share is presented, as the Company did not have any potential ordinary shares outstanding.
 
STATEMENT OF DIRECTORS’ RESPONSIBILITIES
 
The Directors confirm that this condensed set of financial statements has been prepared in accordance with International Financial Reporting Standards and IAS 34 Interim Financial Reporting, and that the interim condensed financial statements herein give a true and fair view of the assets, liabilities, financial position and profit and loss of the Group.
 
PUBLICATION OF NON-STATUTORY ACCOUNTS
 
The unaudited interim results do not constitute full accounts prepared in accordance with the listing rules of the UK Financial Services Authority. The figures for the year ended 31 December 2007 have been based on the full accounts of the Company which were prepared under IFRS and which included an unqualified audit report. The interim financial information in this report has been neither audited nor reviewed by the Company’s auditors.
 
Copies of this report have been sent to shareholders and are available to the public from the Company’s UK Transfer Agents, Capita Registrars, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FKCKBNBKDFFB
Date   Source Headline
29th Jan 20187:18 amRNSLansen Change of Director
27th Dec 201712:39 pmRNSUpdate on Settlement of A Litigation
22nd Sep 201711:05 amRNSResults of Special General Meeting
19th Sep 201710:15 amRNSLansen's second share reduction plan of Starry
1st Sep 20173:11 pmRNSUpdate on Litigation against Lansen's subsidiary
30th Aug 20179:48 amRNSInterim Results for Six Months Ended 30 June 2017
30th Aug 20179:45 amRNSNotice of Special General Meeting
16th Aug 20177:00 amRNSNotice of Results
21st Jun 201711:55 amRNSResult of AGM
20th Jun 20177:00 amRNSSettlement of insurance claims received by Lansen
19th Jun 201711:54 amRNSLansen's declaration & payment of special dividend
7th Jun 201710:14 amRNSLansen's proposal to approve a special dividend
28th Apr 20177:00 amRNSAnnual Report and Accounts
7th Apr 201711:37 amRNSHoldings in Company
31st Mar 20179:50 amRNSLansen subsidiary enters distribution agreement
30th Mar 20179:20 amRNSAnnual Results for the Year Ended 31 December 2016
16th Mar 20177:00 amRNSNotice of Annual Results 2016
15th Mar 201711:57 amRNSNotification of class 2 transaction
9th Mar 20179:05 amRNSLansen's share reduction plan of Starry
20th Sep 201610:44 amRNSEntrusted Manufacturing Framework Agreement
31st Aug 20169:48 amRNSHalf-year Report
17th Aug 20167:00 amRNSNotice of Interim Results 2016
13th Jul 201611:02 amRNSResult of Lansen EGM
24th Jun 20161:15 pmRNSLansen Shares Subscription and Agreement
20th Jun 201611:17 amRNSResult of AGM
5th May 20161:00 pmRNSNotification of Transactions
5th May 20161:00 pmRNSClarification Announcement - transaction in Shares
5th May 20161:00 pmRNSNotification of Transactions
22nd Apr 20168:10 amRNSAnnual Report and Accounts
5th Apr 201610:11 amRNSDirector Appointment
30th Mar 201610:01 amRNSAnnual Results for the Year Ended 31 December 2015
24th Mar 20169:21 amRNSNotification of class 2 transaction
16th Mar 201610:01 amRNSNotice of Annual Results 2015
9th Mar 201610:04 amRNSStarry IPO
7th Mar 201610:34 amRNSLansen's release of its Trading Update
17th Feb 20168:50 amRNSLansen's Starry, obtains listing approval
29th Dec 20158:45 amRNSTrading Update
1st Dec 20155:51 pmRNSHolding(s) in Company
28th Aug 201510:12 amRNSHalf Yearly Report
17th Aug 20157:00 amRNSNotice of Interim Results
6th Jul 201510:25 amRNSLitigation against Lansen's sub in Ningbo, the PRC
15th Jun 20151:18 pmRNSLansen enters a distribution agreement with Botai
11th Jun 20159:38 amRNSDistribution agreement with Bio-Rad China
5th Jun 20157:01 amRNSAppointment of New Chairman
5th Jun 20157:00 amRNSResult of AGM
11th May 20157:00 amRNSAppointment of Broker
17th Apr 20159:03 amRNSTransaction in Own Shares
16th Apr 20153:44 pmRNSAnnual Report and Accounts
15th Apr 20158:59 amRNSTransaction in Own Shares
9th Apr 20157:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.